NO20053837L - Farmasoytisk blanding for profylakse eller behandling av kardiovaskulaere-, kardiopulmonaere-, pulmonaere- eller nyresykdommer. - Google Patents

Farmasoytisk blanding for profylakse eller behandling av kardiovaskulaere-, kardiopulmonaere-, pulmonaere- eller nyresykdommer.

Info

Publication number
NO20053837L
NO20053837L NO20053837A NO20053837A NO20053837L NO 20053837 L NO20053837 L NO 20053837L NO 20053837 A NO20053837 A NO 20053837A NO 20053837 A NO20053837 A NO 20053837A NO 20053837 L NO20053837 L NO 20053837L
Authority
NO
Norway
Prior art keywords
cardiopulmonary
prophylaxis
cardiovascular
treatment
hmg
Prior art date
Application number
NO20053837A
Other languages
English (en)
Norwegian (no)
Inventor
Michael Mark
Axel Riedel
Josep-Maria Sendra
Josef M E Leiter
Stefan Kauschke
Original Assignee
Boeheringer Ingelheim Internat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10335027A external-priority patent/DE10335027A1/de
Application filed by Boeheringer Ingelheim Internat filed Critical Boeheringer Ingelheim Internat
Publication of NO20053837L publication Critical patent/NO20053837L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20053837A 2003-01-16 2005-08-15 Farmasoytisk blanding for profylakse eller behandling av kardiovaskulaere-, kardiopulmonaere-, pulmonaere- eller nyresykdommer. NO20053837L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10301371A DE10301371A1 (de) 2003-01-16 2003-01-16 Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
DE10335027A DE10335027A1 (de) 2003-07-31 2003-07-31 Verwendung von Angiotensin II Rezeptor Antagonisten
PCT/EP2004/000174 WO2004062557A2 (de) 2003-01-16 2004-01-14 Pharmazeutische kombination aus telmisartan und atorvastatinph zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten

Publications (1)

Publication Number Publication Date
NO20053837L true NO20053837L (no) 2005-08-15

Family

ID=32714791

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053837A NO20053837L (no) 2003-01-16 2005-08-15 Farmasoytisk blanding for profylakse eller behandling av kardiovaskulaere-, kardiopulmonaere-, pulmonaere- eller nyresykdommer.

Country Status (21)

Country Link
US (1) US20040259925A1 (ru)
EP (1) EP1587479B1 (ru)
JP (1) JP2006515614A (ru)
KR (1) KR20050092121A (ru)
CN (1) CN1738617A (ru)
AT (1) ATE536871T1 (ru)
AU (1) AU2004204352B2 (ru)
BR (1) BRPI0406455A (ru)
CA (1) CA2513277A1 (ru)
DE (1) DE10301371A1 (ru)
EA (1) EA009874B1 (ru)
EC (1) ECSP055915A (ru)
HR (1) HRP20050654A2 (ru)
MX (1) MXPA05007103A (ru)
NO (1) NO20053837L (ru)
NZ (1) NZ541747A (ru)
PL (1) PL378225A1 (ru)
RS (1) RS20050537A (ru)
UA (1) UA84282C2 (ru)
WO (1) WO2004062557A2 (ru)
ZA (1) ZA200503542B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US9029363B2 (en) * 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
WO2004106299A2 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as hmg-co inhibitors
UA89065C2 (ru) * 2004-11-05 2009-12-25 Бёрингэр Ингэльхайм Интэрнациональ Гмбх Двухслойная таблетка, которая содержит телмисартан и амлодипин
WO2006050923A1 (en) * 2004-11-11 2006-05-18 Lek Pharmaceuticals D.D. Polymorph form of irbesartan
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
RU2453307C2 (ru) * 2006-10-30 2012-06-20 Ханол Биофарма Ко.Лтд Комплексная фармацевтическая композиция с контролируемым высвобождением, содержащая блокаторы рецепторов ангиотензина-ii и ингибиторы гидроксиметилглутарил-кофермент а-редуктазы
JP5460600B2 (ja) 2007-09-28 2014-04-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 肥満症治療における肥満細胞安定化薬
KR100893652B1 (ko) 2008-11-10 2009-04-17 주식회사종근당 신규한 텔미사르탄 아연염 및 그의 제조방법
CZ301299B6 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
CN102028682A (zh) * 2010-12-16 2011-04-27 施慧达药业集团(吉林)有限公司 一种包含替米沙坦和阿托伐他汀的复方药物制剂
EP2787993B1 (en) 2011-12-09 2016-11-23 Artskin D.O.O. TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
WO2019018849A1 (en) * 2017-07-21 2019-01-24 Kieu Hoang STATINES (ATORVASTATIN) THAT CAN REDUCE GLYCEMIA LEVEL IN DIABETICS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT914158E (pt) * 1996-04-05 2002-11-29 Takeda Chemical Industries Ltd Combinacao farmaceutica que incorpora um composto que possui actividade antagonista da angiotensina ii e um composto que aumenta a sensibilidade a insulina
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
EE05670B1 (et) * 1999-08-30 2013-08-15 Aventis Pharma Deutschland Gmbh Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
PL365696A1 (en) * 2000-04-12 2005-01-10 Novartis Ag Combination of organic compounds
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JP4585198B2 (ja) * 2002-12-27 2010-11-24 武田薬品工業株式会社 体重増加抑制剤

Also Published As

Publication number Publication date
AU2004204352B2 (en) 2009-07-30
US20040259925A1 (en) 2004-12-23
CA2513277A1 (en) 2004-07-29
EP1587479A2 (de) 2005-10-26
WO2004062557A3 (de) 2004-09-16
ZA200503542B (en) 2006-07-26
HRP20050654A2 (en) 2006-05-31
CN1738617A (zh) 2006-02-22
DE10301371A1 (de) 2004-08-05
NZ541747A (en) 2009-09-25
RS20050537A (en) 2007-09-21
WO2004062557A2 (de) 2004-07-29
KR20050092121A (ko) 2005-09-20
ATE536871T1 (de) 2011-12-15
EA200501058A1 (ru) 2006-02-24
BRPI0406455A (pt) 2005-12-06
UA84282C2 (ru) 2008-10-10
EP1587479B1 (de) 2011-12-14
EA009874B1 (ru) 2008-04-28
AU2004204352A1 (en) 2004-07-29
MXPA05007103A (es) 2005-08-26
PL378225A1 (pl) 2006-03-20
JP2006515614A (ja) 2006-06-01
ECSP055915A (es) 2006-03-01

Similar Documents

Publication Publication Date Title
NO20053837L (no) Farmasoytisk blanding for profylakse eller behandling av kardiovaskulaere-, kardiopulmonaere-, pulmonaere- eller nyresykdommer.
WO2005082863A3 (en) 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
NO20161634A1 (no) 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt
NO20073932L (no) Fuserte bicykliske karboksamidderivater for anvendelse som CXCR2 inhibitorer i behandlingen av inflammasjon
ES2196917T3 (es) Amidas heteroaromaticas como inhibidores del factor xa`.
NO20051726L (no) Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
SI1587584T1 (sl) Farmacevtska kombinacija za profilakso ali terapijo kardiovaskularnih, kardiopulmonalnih, pulmonalnih ali renalnih bolezni
NO20055565L (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
DE50312935D1 (de) Zusammensetzungen zur hemmung der proteinkinase c alpha zur behandlung von diabetes mellitus
DE60315336D1 (de) Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
WO2004052853A3 (en) Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
NO20050579L (no) Indolinfenylsulfonamidderivater
NO20034986L (no) Furan og tiofenderivater som aktiverer human peroksisom proliferator aktiverte reseptorer
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
JP2007277267A5 (ru)
DE60329330D1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
ATE327225T1 (de) Neue verwendung von benzothiazolderivaten
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
AR038305A1 (es) Composicion farmaceutica dispersable oralmente de perindopril
RU2006117790A (ru) Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением
DE60316436D1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
DE50100678D1 (de) 4-pyridyl- und 2,4-pyrimidinyl-substituierte pyrrolderivate und ihre anwendung in der pharmazie
WO2000048447A3 (en) Composition for treatment of external secretion disorders except hypolacrimation
SE0201939D0 (sv) New combination

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application